• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>IEEE Nuclear Science Symposium >Purification and Laser Isotope Separation of 176{sup left}Yb for Medical Applications
【24h】

Purification and Laser Isotope Separation of 176{sup left}Yb for Medical Applications

机译：用于医疗应用的176 {SUP左} YB的纯化和激光同位素分离

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

These days, new medical technologies using radio-isotopes (RI) have been developed for an imaging and treatment for several cancers. They have led to an increase in the usage of the enriched stable isotopes as the source materials for the radioisotopes. Especially, the radioisotope, 177{sup left}Lu, is emerging as an important candidate for a broad therapeutic use such as prostate, breast, colon, and brain cancer because of its several outstanding features [1]. 177{sup left}Lu can be produced in a reactor by a direct (n, γ) neutron radiation of the stable isotope 176{sup left}Lu. However, in the process, only about 20% of the 176{sup left}Lu atoms are converted to the radio-active 177{sup left}Lu and the long-lived impurity (177m){sup left}Lu isotopes are also produced. Moreover, it is very difficult to separate the pure 177{sup left}Lu from the remaining stable 176{sup left}Lu and the impurity radio-isotope since all the compounds are chemically equivalent. Another method for the production of 177{sup left}Lu is through an indirect process starting from the Yb isotope [2]. The stable 176{sup left}Yb isotope can be converted to 177{sup left}Yb by the (n, γ) reaction and it is spontaneously converted to 177{sup left}Lu accompanied by a β{sup}- decay with a half-life of about 2 hours. When we use this indirect process, it is feasible to separate 177{sup left}Lu from 176{sup left}Yb due to the chemical differences between Yb and Lu. Therefore, it is possible to produce a carrier-free therapeutic radioisotope 177{sup left}Lu that does not contain a non-radioactive isotope. For these reasons, it is better that we choose the indirect process using 176{sup left}Yb to produce 177{sup left}Lu. Therefore, research on the indirect process and the related chemical separation of Yb and Lu are on-going world-wide [3-4].
机译：如今，已经开发了使用无线电同位素（RI）的新医疗技术用于几种癌症的成像和治疗。它们导致富含富含稳定同位素的用途的增加作为放射性同位素的源材料。特别是，放射性同位素，177 {Sup离开} Lu，作为广泛治疗使用的重要候选者，如前列腺，乳腺，结肠和脑癌，因为它的几个出色的功能[1]。可以通过稳定同位素176的直接（n，γ）中子辐射，在反应器中产生177 {sup左} lu。然而，在该过程中，只有约20％的176 {sup} Lu原子被转换为无线电有效的177 {sup左} lu和长寿命的杂质（177m）{sup左} lu同位素也是由同位素产生的。此外，从剩余的稳定176 {sup左} Lu和杂质无线电同位素非常难以将纯177 {sup左} Lu分离，因为所有化合物都是化学等同的。另一种制备177 {SUP左} Lu的方法是从YB同位素开始的间接过程[2]。稳定的176 {sup左} yb同位素可以通过（n，γ）反应转换为177 {sup左} Yb，并且它被自发地转换为177 {sup左} lu伴随着β{sup} - 腐烂半衰期约2小时。当我们使用这个间接过程时，由于YB和LU之间的化学差异，可以将177 {SUP左} LU分开177 {SUP左} LU是可行的。因此，可以产生不含非放射性同位素的无载体的治疗性放射性同位素177 {sup左} Lu。由于这些原因，我们最好选择使用176 {sup} yb来生成177 {sup left} lu的间接进程。因此，对间接过程和YB和Lu相关化学分离的研究正在展望全球[3-4]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号